Research
Cellular
Gastrointestinal adverse events were reported in 79.6% of the cagrilintide-semaglutide group and 39.9% in the placebo group.
Clinicians should monitor for gastrointestinal side effects in patients receiving cagrilintide-semaglutide.
StrongSupportsmedium confidence
Gastrointestinal adverse events (affecting 79.6% in the cagrilintide-semaglutide group and 39.9% in the placebo group) were mainly transient and mild-to-moderate in severity.
Why this rating
Based on a phase 3a, multicenter, double-blind, placebo-controlled trial.
Source
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
W. Timothy Garvey et al. · New England Journal of Medicine · 2025
DOI 10.1056/nejmoa2502081
rct · n=3417Cited 138×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Cagrilintide-semaglutide resulted in a mean percent change in body weight of -20.4% from baseline to week 68 compared to -3.0% with placebo.Strong
- Participants receiving cagrilintide-semaglutide were more likely to achieve weight-loss targets of 5%, 20%, 25%, and 30% or more compared to placebo.Strong
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →